Nutriband Inc. 8-K Filing Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Nutriband Inc. (Nasdaq: NTRB) on August 5, 2025. The company, incorporated in Nevada, is an emerging growth company focused on transdermal pharmaceutical products utilizing its AVERSA™ abuse deterrent technology. The report details corporate actions taken in July 2025 regarding the authorization and distribution of a new class of preferred stock.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and capital structure changes rather than operational financial performance.
Material Changes
- Authorization of Series A Preferred Stock: On July 9, 2025, the Board amended the Articles of Incorporation to authorize Series A Convertible Preferred Stock. The initial authorization was 2,788,678 shares, which was subsequently increased to 10,000,000 shares via a Certificate of Correction filed on July 21, 2025.
- Stock Dividend Distribution: On July 25, 2025, the company completed a stock dividend of Series A Preferred Stock to shareholders of record. The ratio was one share of Series A Preferred Stock for every four shares of common stock held. A total of 3,008,643 shares were issued, with fractional shares rounded down.
- Conversion Terms: The Series A Preferred Stock is non-voting and convertible into one share of Common Stock at the holder's option following FDA approval for commercial sale of the company's AVERSA™ based products.
- Dividend Rights: Holders of unconverted Series A Preferred Stock are eligible for dividends declared by the Board for that class, as well as dividends declared on the common stock class.
Guidance, Outlook, and Risks
Outlook and Contingencies: The conversion of the Series A Preferred Stock is contingent upon the Federal Drug Administration (FDA) granting approval for commercial sale of the company's transdermal pharmaceutical products. Until this approval is received, the preferred shares remain non-convertible.
Restrictions: The shares issued in the dividend are held as restricted stock by the transfer agent, Equinity Trust Company, LLC. They are not issuable or transferable to recipients until the shares are eligible for conversion, the company completes SEC registration, and the shares are listed for trading on Nasdaq.
Risks: The filing does not explicitly list new risk factors, but the value and liquidity of the new preferred shares are entirely dependent on future regulatory approval and successful registration.
Investor Verification Checklist
- Verify the exact number of common shares held to calculate the specific number of Series A Preferred shares received in the dividend.
- Confirm the current status of the FDA application for AVERSA™ based products, as this triggers the conversion right.
- Monitor future filings for the SEC registration statement required to make the restricted preferred shares tradable.
- Review the amended Articles of Incorporation (Exhibit 3.1D) and Certificate of Correction (Exhibit 3.1E) for full legal terms of the Series A Preferred Stock.